加速康复计划下电视辅助胸腔镜肺叶切除术后存活且未住院天数
该回顾性研究纳入316例在成熟加速康复外科(ERAS)计划下接受电视辅助胸腔镜(VATS)肺叶切除术的非小细胞肺癌患者,评估术后365天内存活且未住院天数(DAOH)。术后365天DAOH中位数为359天(IQR 349-363),主要降低DAOH的因素为漏气、辅助化疗副作用和复发转移。低一氧化碳弥散量和既往手术史是低DAOH的预测因素。
要点
- 术后365天DAOH中位数为359天(IQR 349-363),仅较满分减少6天。
- 术后0-30天和0-365天降低DAOH的主要因素均为漏气(47.2%和38.3%)。
- 低一氧化碳弥散量和既往手术史是低DAOH的预测因素。
核心结论
- 在成熟的VATS肺叶切除ERAS计划下,术后1年DAOH中位数仅减少6天,主要降低因素为漏气、辅助化疗和复发,DAOH可能是有助于定义未来改进策略的重要以患者为中心的结局指标。
研究设计与样本
- 回顾性评估316例年龄≥18岁、符合明确纳入标准且随访完整的非小细胞肺癌患者,均在成熟ERAS计划下接受VATS肺叶切除术。
主要发现
- 术后30、60、90、180和365天DAOH中位数(IQR)分别为27(22-28)、57(51-58)、86(80-88)、176(169-178)和359(349-363)天,中位住院时间为3天(IQR 2-6)。
- 术后0-30天和0-365天降低DAOH的主要因素为漏气(47.2%和38.3%),术后31-60天和61-90天为辅助化疗副作用(23.5%和47.1%),术后91-180天和181-365天为复发/转移(25.6%和50.0%)。
- 低一氧化碳弥散量(OR 1.28,95%CI 1.07-1.53;P=0.007)和既往手术史(OR 1.80,95%CI 1.08-2.99;P=0.023)是低DAOH的预测因素。
临床怎么用
- 原文结论指出DAOH可能是有助于定义未来改进策略的重要以患者为中心的结局指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Days alive and out of hospital (DAOH) integrates overall information of hospitalization, readmissions, and mortality that have been applied as a new outcome measure. However, DAOH after video-assisted thoracoscopic surgery (VATS) in an established enhanced recovery after surgery (ERAS) programme has not been reported. METHODS: Patients aged ≥18 years with non-small-cell lung cancer undergoing VATS lobectomy in an established ERAS programme were eligible. The primary and secondary outcomes were DAOH during the first postoperative 365 days and reasons for reduced DAOH. RESULTS: A total of 316 consecutive patients with well-defined inclusion criteria and complete follow-up were assessed retrospectively. The median length of stay was 3 days (IQR 2-6). The medians (IQR) of postoperative 30, 60, 90, 180 and 365 DAOH were 27 (22-28), 57 (51-58), 86 (80-88), 176 (169-178) and 359 (349-363) days, respectively. Air leak was the dominant factor for reduced DAOH from postoperative day (POD) 0-30 (47.2%) and 0-365 (38.3%). Side effects of adjuvant chemotherapy were dominant from POD 31-60 and 61-90 (23.5% and 47.1%) and recurrence/metastases from POD 91-180 and 181-365 (25.6% and 50.0%). A low diffusing capacity for carbon monoxide (odds ratios 1.28, 95% confidence interval 1.07-1.53; P=0.007) and prior surgical history (odds ratios 1.80, 95% confidence interval 1.08-2.99; P=0.023) were predictors for low DAOH. CONCLUSIONS: DAOH after 1 year with an established VATS lobectomy ERAS programme was only reduced with a median of 6 days. The main factors reducing DAOH were air leak, adjuvant chemotherapy and recurrence. DAOH may be an important patient-centred outcome to define future improvement strategies.
引用
- Huang L, Frandsen MN, Kehlet H, et al. Days alive and out of hospital after enhanced recovery video-assisted thoracoscopic surgery lobectomy. Eur J Cardiothorac Surg. 2022. PMID: 35234866. doi:10.1093/ejcts/ezac148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。